drugset / Trial / NCT00516386

Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents

NCT00516386

Phase 1/2 Completed 16 enrolled Massachusetts General Hospital Tercica · collab
NaSingle-groupOpen-labelOther

Summary

The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.

Timeline

Start
2007-03
Primary completion
2008-05
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mecasermin Protein / enzyme biologic 35 ug/kg Subcutaneous
Subject mecasermin Protein / enzyme biologic 40 ug/kg Subcutaneous

Indications